Alaunos Therapeutics (TCRT) Income from Continuing Operations (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Income from Continuing Operations came in at 1031000.0 in Q1 2026, up 5.59% YoY from 976454.47 in Q1 2025, and down 13.67% on a QoQ basis from 907000.0 in Q4 2025.
Alaunos Therapeutics (TCRT) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Income from Continuing Operations data on file, last reported at 1031000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 5.59% year-over-year to 1031000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73191000.0 (down 1658.13% YoY) and the FY2025 annual result came in at 217809000.0, down 4426.37% from the prior year.
- Income from Continuing Operations eased to 1031000.0 in Q1 2026, from 907000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 755000.0 in Q4 2024 to a low of 70054000.0 in Q2 2025.
- A 5-year average of 9044000.0 and a median of 8091000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 90.67% — and 2025, when it plunged 5908.06%.
- Tracing TCRT's Income from Continuing Operations over 5 years: stood at 9421000.0 in 2022, then rose by 14.12% to 8091000.0 in 2023, then soared by 90.67% to 755000.0 in 2024, then fell by 20.13% to 907000.0 in 2025, then retreated by 13.67% to 1031000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1031000.0 (Q1 2026), 907000.0 (Q4 2025), and 1199000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | -952,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | -907,000.00 |
| Sep 30, 2025 | -1.20 Mn |
| Jun 30, 2025 | -70.05 Mn |
| Mar 31, 2025 | -1.09 Mn |
| Dec 31, 2024 | -755,000.00 |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -1.17 Mn |
| Mar 31, 2024 | -1.74 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Sep 30, 2023 | -8.66 Mn |
| Jun 30, 2023 | -9.08 Mn |
| Mar 31, 2023 | -10.57 Mn |
| Dec 31, 2022 | -9.42 Mn |
| Sep 30, 2022 | -9.06 Mn |
| Jun 30, 2022 | -9.97 Mn |
| Mar 31, 2022 | -9.79 Mn |
| Dec 31, 2021 | -11.81 Mn |
| Sep 30, 2021 | -22.74 Mn |
| Jun 30, 2021 | -23.81 Mn |